SEC Tracker
Get the app

Equillium EQ

Equillium (EQ) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational status. The filing highlights Equillium's progress in advancing its clinical pipeline and managing its financial resources, which is crucial for investors to assess the company's near-term prospects and long-term growth potential.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Equillium files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zeo ScientifiX ZEOX public float $7M, Apr 30, 2025, over 18 months old
  2. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  3. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  4. CV Sciences CVSI public float $7M, Jun 30, 2025
  5. Minerva Neurosciences NERV public float $7M, Jun 30, 2025